267 related articles for article (PubMed ID: 23178489)
1. The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.
Lin MZ; Marzec KA; Martin JL; Baxter RC
Oncogene; 2014 Jan; 33(1):85-96. PubMed ID: 23178489
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
[TBL] [Abstract][Full Text] [Related]
3. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.
Marzec KA; Lin MZ; Martin JL; Baxter RC
Oncotarget; 2015 Sep; 6(29):26583-98. PubMed ID: 26378048
[TBL] [Abstract][Full Text] [Related]
4. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
5. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
6. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
[TBL] [Abstract][Full Text] [Related]
7. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
[TBL] [Abstract][Full Text] [Related]
8. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
[TBL] [Abstract][Full Text] [Related]
9. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.
Cobb LJ; Liu B; Lee KW; Cohen P
Cancer Res; 2006 Nov; 66(22):10878-84. PubMed ID: 17108124
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity.
Dittmann K; Mayer C; Rodemann HP
Radiother Oncol; 2005 Aug; 76(2):157-61. PubMed ID: 16024112
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Kriegs M; Kasten-Pisula U; Rieckmann T; Holst K; Saker J; Dahm-Daphi J; Dikomey E
DNA Repair (Amst); 2010 Aug; 9(8):889-97. PubMed ID: 20615764
[TBL] [Abstract][Full Text] [Related]
14. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
16. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
17. A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation.
Kim CH; Park SJ; Lee SH
J Pharmacol Exp Ther; 2002 Nov; 303(2):753-9. PubMed ID: 12388662
[TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
19. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade.
Um JH; Kwon JK; Kang CD; Kim MJ; Ju DS; Bae JH; Kim DW; Chung BS; Kim SH
J Pharmacol Exp Ther; 2004 Dec; 311(3):1062-70. PubMed ID: 15273254
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
